H1
H2
H3
H4
H5
H6
Text Size h1
Text Size h2
Text Size h3
Text Size h4
Text Size h5
Text Size h6
Body text placeholder. ---- Lorem ipsum dolor sit amet, consectetur adipiscing elit. Duis ut sodales ipsum. Fusce tempor laoreet elit ut mattis. Suspendisse ac lacinia nulla. In maximus ex at pretium volutpat. Quisque imperdiet vel nisl semper eleifend. In maximus ex at pretium volutpat. Quisque imperdiet vel nisl semper eleifend.
Paragraph - Body. ---- Lorem ipsum dolor sit amet, consectetur adipiscing elit. Duis ut sodales ipsum. Fusce tempor laoreet elit ut mattis. Suspendisse ac lacinia nulla. In maximus ex at pretium volutpat. Quisque imperdiet vel nisl semper eleifend. In maximus ex at pretium volutpat. Quisque imperdiet vel nisl semper eleifend.
Content with image on right
Our Investment Proposition
At Scibase we are on a mission to improving patient's lives through developing accurate detection of skin conditions. We are experiencing rapid growth in our core European market, particularly Germany. Our EU product usage increased in 2022 where we welcomed over 50% new customers. We proudly hold MDR certification in Europe which decreases the barrier to entry for competitors. Our product Nevisense is the only point of care device available for melanoma detection in the US and our presence in the US market holds immense growth potential.
Content with image on left
Our Investment Proposition Left
At Scibase we are on a mission to improving patient's lives through developing accurate detection of skin conditions. We are experiencing rapid growth in our core European market, particularly Germany. Our EU product usage increased in 2022 where we welcomed over 50% new customers. We proudly hold MDR certification in Europe which decreases the barrier to entry for competitors. Our product Nevisense is the only point of care device available for melanoma detection in the US and our presence in the US market holds immense growth potential.
Signpost cards 2
Market Overview
Board of Directors
Simple Table
| Title | Item | Item | Item | Item |
|---|---|---|---|---|
| 2 Mar 2022 | Item | Item | Item | Item |
| 2 Mar 2022 | Item | Item | Item | Item |
| 2 Mar 2022 | Item | Item | Item | Item |
| 2 Mar 2022 | Item | Item | Item | Item |
Accordion
Product portfolio
Nevisense is a non-invasivemedical device designed to assist healthcare professionals in the early detection and assessment of skin conditions, with a primary focus on melanoma, a potentially life-threatening form of skin cancer.
The Nevisense device utilizes a technology called electrical impedance spectroscopy to examine and analyze the electrical properties of skin lesions. By assessing these properties, Nevisense provides real-time data that can aid healthcare professionals in distinguishing between benign and potentially malignant skin lesions.
This technology enables healthcare providers to make more informed decisions regarding the need for further evaluation, biopsies, or treatments.
Nevisense Go Platform Nevisense Go PlatformNevisense Go PlatformNevisense Go PlatformNevisense Go PlatformNevisense Go PlatformNevisense Go PlatformNevisense Go PlatformNevisense Go PlatformNevisense Go Platform Nevisense is a non-invasivemedical device designed to assist healthcare professionals in the early detection and assessment of skin conditions, with a primary focus on melanoma, a potentially life-threatening form of skin cancer.
The Nevisense device utilizes a technology called electrical impedance spectroscopy to examine and analyze the electrical properties of skin lesions. By assessing these properties, Nevisense provides real-time data that can aid healthcare professionals in distinguishing between benign and potentially malignant skin lesions.
Key figures
Content
Commitment to improving patients' lives
Our commitment extends beyond technology. We understand the importance of collaboration between patients, physicians, and technology in the pursuit of healthier skin. By partnering with healthcare providers and institutions, we are working towards a world where skin diseases are detected early, treated effectively, and lives are improved.
Global Reach, Local impact
Headquartered in Sweden, SciBase operates on a global scale. We are dedicated to making our innovative solutions accessible to medical practitioners and patients worldwide.
Our Focus areas on clinical application within skin barrier segment
- Infant AD prediction - strategic collaboration with J&J consumer health
- Objective AD assessment and management
- In-home AD flare predictions and management
Precision and Accuracy
The Nevisense system utilizes a technology called Electrical Impedance Spectroscopy (EIS) to analyze the electrical properties of the skin. This technology involves the application of a small electrical current to the skin's surface through the proprietary Nevisense electrodes. The key significance of these electrodes lies in their ability to provide valuable insights into the condition of the skin. By analyzing the electrical properties of the skin, including its moisture content and cellular structure, the Nevisense system can detect subtle changes or abnormalities that may not be visible to the naked eye.
Form Element Test Page
Signpost cards 1
Sweden
Tabs
| Date | Title | Report | Press Release | PPT | Webcast Audio | Webcast video |
|---|---|---|---|---|---|---|
| Annual report 2020 | Release | SciBase publishes the Annual report for 2020 | ||||
| Year-end report 2020 | Report (PDF) | Year-end report | ||||
| Interim Report Q3 2020 | Report (PDF) | Interim report | ||||
| Interim Report Q2 2020 | Report | Interim report | ||||
| Interim Report Q1 2020 | Report | Interim report |
| Date | Title | Report | Press Release | PPT | Webcast Audio | Webcast video |
|---|---|---|---|---|---|---|
| Annual report 2020 | Release | SciBase publishes the Annual report for 2020 | ||||
| Year-end report 2020 | Report (PDF) | Year-end report | ||||
| Interim Report Q3 2020 | Report (PDF) | Interim report | ||||
| Interim Report Q2 2020 | Report | Interim report | ||||
| Interim Report Q1 2020 | Report | Interim report |
| Date | Title | Report | Press Release | PPT | Webcast Audio | Webcast video |
|---|---|---|---|---|---|---|
| Capital Markets Day 2024 | ||||||
| Redeye Theme: Fight Cancer |
| Date | Title | Report | Press Release | PPT | Webcast Audio | Webcast video |
|---|---|---|---|---|---|---|
| CFO Michael Colérus Presents at Redeye Life Science Dy Nov 11, 2021 | ||||||
| Redeye: Interview with CEO Simon Grant 11 May, 2021 | ||||||
| Online Capital Market Conference Family Office Day on 14 April 2021 | ||||||
| Redeye: Interview with CEO Simon Grant |
AR Signpost
Calendar
| DATE | TITLE | Calendar Alert | |
|---|---|---|---|
| 10 Nov 2023 | Interim report Q3 2023 | Interim report Q3 2023
Interim report Q3 2023
|
|
| 10 Nov 2023 | Delårsrapport januari - september 2023 | Delårsrapport januari - september 2023
Delårsrapport januari - september 2023
|
|
| 18 Aug 2023 | Interim report Q2 2023 | Interim report Q2 2023
Interim report Q2 2023
|
|
| 18 Aug 2023 | Delårsrapport januari - juni 2023 | Delårsrapport januari - juni 2023
Delårsrapport januari - juni 2023
|
|
| 21 Feb 2024 | Year-end report 2023 | Year-end report 2023
Scibase Year-end report
|
|
| 21 Feb 2024 | Bokslutskommuniké 2023 | Bokslutskommuniké 2023
Scibase Bokslutskommuniké 2023
|
|
| 31 May 2024 | Interim report Q1 2024 | Interim report Q1 2024
Interim report Q1 2024
|
|
| 31 May 2024 | Delårsrapport januari - mars 2024 | Delårsrapport januari - mars 2024
Delårsrapport januari - mars 2023
|
|
| 21 Aug 2024 | Interim report Q2 2024 | Interim report Q2 2024
Interim report Q2 2024
|
|
| 21 Aug 2024 | Delårsrapport januari - juni 2024 | Delårsrapport januari - juni 2024
Delårsrapport januari - juni 2024
|
Press archive
Calendar
| DATE | TITLE | Calendar Alert |
|---|---|---|
| 07 May 2026 | Interim report Q1 2026 | Interim report Q1 2026
Interim report Q1 2026
|
| 19 May 2026 | Annual General Meeting 2026 | Annual General Meeting 2026
Annual General Meeting 2026
|
| DATE | TITLE | Calendar Alert |
|---|---|---|
13 Mar 2026 |
Year-end report 2025 | Year-end report 2025
Year-end report 2025
|
07 Nov 2025 |
Interim report Q3 2025 | Interim report Q3 2025
Interim report Q3 2025
|
19 Aug 2025 |
Interim report Q2 2025 | Interim report Q2 2025
Interim report Q2 2025
|
17 Jun 2025 |
Annual General Meeting 2025 | Annual General Meeting 2025
Annual General Meeting 2025
|
13 May 2025 |
Interim report Q1 2025 | Interim report Q1 2025
Interim report Q1 2025
|
25 Feb 2025 |
Year-end report 2024 | Year-end report 2024
Year-end report 2024
|
12 Nov 2024 |
Interim report Q3 2024 | Interim report Q3 2024
Interim report Q3 2024
|
21 Aug 2024 |
Interim report Q2 2024 | Interim report Q2 2024
Interim report Q2 2024
|
13 Jun 2024 |
Annual General Meeting 2024 | Annual General Meeting 2024
Annual General Meeting 2024
|
31 May 2024 |
Interim report Q1 2024 | Interim report Q1 2024
Interim report Q1 2024
|